Optibrium -Augmented Chemistry Software
FromOptibrium Ltd.
Cerella™ uses a unique deep learning approach to overcome limitations in drug discovery data, reducing costs and accelerating drug discovery cycles. Cerella highlights high-quality compounds with confidence, finding hidden opportunities caused by missing, uncertain or inaccurate data and prioritises the most valuable experiments.
Most popular related searches
Reducing the time and cost of your discovery cycles
Cerella can:
- Proactively highlight high-quality compounds by ‘filling in’ sparse data
- Increase confidence in decision making, identify hidden opportunities, flag outliers and false negatives
- Help you translate AI insights into the planning of experiments to focus on he most valuable measurements
- Enable you to gain more value from your compound data, accurately predicting complex endpoints, intractable with conventional QSAR modeling
- Add value at any scale, from individual project datasets to global compound data repositories
Cerella offers cloud-enabled deployment, scaling from individual projects to global pharma databases. Data in the cloud are anonymised and fully encrypted in transit and at rest, and a multi-level security model controls access.
Cerella uses a unique, peer-reviewed deep learning method, with demonstrated successes in drug discovery.
Cerella™ is powered by Alchemite™, a deep learning method developed by Optibrium’s technology partner Intellegens Limited. In collaboration with pharmaceutical and biotechnology partners, Optibrium has rigorously demonstrated Alchemite’s unique benefits over conventional modelling methods in peer-reviewed studies, resulting in reductions in cost and time of discovery cycles. Cerella™ has proven its benefits in several collaborations with pharma and biotech organisations, working with individual project-level datasets up to global compound data repository level investigations.